Insider Selling: Moderna (NASDAQ:MRNA) Insider Sells 3,471 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.16 during trading hours on Monday, reaching $47.60. The stock had a trading volume of 3,926,335 shares, compared to its average volume of 9,185,553. The firm has a market cap of $18.89 billion, a price-to-earnings ratio of -5.84 and a beta of 1.05. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $59.55. The firm has a 50-day moving average of $49.83 and a 200-day moving average of $43.31.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The business had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business’s revenue was up 260.2% on a year-over-year basis. During the same quarter last year, the business posted ($2.52) earnings per share. Equities research analysts predict that Moderna, Inc. will post -6.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent research reports. The Goldman Sachs Group increased their price target on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Evercore set a $35.00 price objective on Moderna in a research report on Tuesday, February 17th. Citigroup reiterated a “neutral” rating on shares of Moderna in a research report on Monday, February 16th. Barclays increased their price objective on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Reduce” and an average target price of $36.60.

Institutional Trading of Moderna

Several large investors have recently bought and sold shares of the company. MUFG Securities EMEA plc purchased a new stake in shares of Moderna in the second quarter valued at $28,000. Flagship Harbor Advisors LLC acquired a new position in Moderna in the fourth quarter valued at $31,000. Canton Hathaway LLC acquired a new position in Moderna in the first quarter valued at $31,000. Ameriflex Group Inc. increased its stake in Moderna by 3,775.0% in the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after purchasing an additional 1,208 shares during the last quarter. Finally, Cromwell Holdings LLC increased its stake in Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after purchasing an additional 341 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.